Entrada Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.75 | -$0.46 | -$0.59 |
| Q2 2024 | 1 | $0.36 | $0.36 | $0.36 |
| Q3 2024 | 1 | -$0.92 | -$0.57 | -$0.73 |
| Q4 2024 | 3 | -$0.70 | -$0.67 | -$0.68 |
| Q1 2025 | 3 | -$0.80 | -$0.67 | -$0.75 |
| Q2 2025 | 2 | -$0.97 | -$0.60 | -$0.77 |
| Q3 2025 | 2 | -$1.01 | -$0.62 | -$0.80 |
| Q4 2025 | 2 | -$1.15 | -$0.71 | -$0.91 |
| Q1 2026 | 1 | -$0.90 | -$0.56 | -$0.72 |
| Q2 2026 | 1 | -$0.93 | -$0.58 | -$0.74 |
| Q3 2026 | 1 | -$1.18 | -$0.73 | -$0.94 |
| Q4 2026 | 1 | -$1.06 | -$0.65 | -$0.84 |
Entrada Therapeutics, Inc. Earnings Date And Information
Entrada Therapeutics, Inc. last posted its earnings results on Tuesday, November 5th, 2024. The company reported $-0.35 earnings per share for the quarter, topping analysts' consensus estimates of $-0.67 by $0.32. The company had revenue of 19.57 M for the quarter and had revenue of 129.01 M for the year. Entrada Therapeutics, Inc. has generated $0 earnings per share over the last year ($-0.2 diluted earnings per share) and currently has a price-to-earnings ratio of 13.73. Entrada Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based on prior year's report dates.
Entrada Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/05/2024 | Q3 2024 | -$0.67 | -$0.35 | 0.32 | $12.32 M | $19.57 M |
| 08/13/2024 | Q2 2024 | $0.14 | $1.61 | 1.47 | $51.86 M | $94.69 M |
| 05/07/2024 | Q1 2024 | -$0.59 | $0.70 | 1.29 | $59.12 M | |
| 03/13/2024 | Q4 2023 | -$0.07 | -$0.29 | -0.22 | $41.85 M | |
| 11/07/2023 | Q3 2023 | -$0.74 | $1.07 | 1.81 | $9.60 M | $43.74 M |
| 08/08/2023 | Q2 2023 | -$0.43 | -$0.78 | -0.35 | $9.78 M | $18.17 M |
| 05/10/2023 | Q1 2023 | -$0.77 | -$0.21 | 0.56 | $25.26 M | |
| 03/06/2023 | Q4 2022 | -$0.84 | -$0.71 | 0.13 | $0 | |
| 11/07/2022 | Q3 2022 | -$0.76 | -$0.75 | 0.01 | $0 | |
| 08/11/2022 | Q2 2022 | -$0.72 | -$0.72 | 0 | $0 | |
| 05/12/2022 | Q1 2022 | -$0.66 | -$0.66 | -0 | $0 | |
| 03/15/2022 | Q4 2021 | -$1.28 | -$0.89 | 0.39 | $0 | |
| 12/09/2021 | Q3 2021 | -$0.87 | -$0.51 | 0.36 | $0 | |
| 06/30/2021 | Q2 2021 | -$0.48 | $0 | |||
| 03/31/2021 | Q1 2021 | -$0.41 | $0 | |||
| 12/30/2020 | Q4 2020 | -$0.42 | $0 | |||
| 09/29/2020 | Q3 2020 | -$0.34 | $0 | |||
| 06/29/2020 | Q2 2020 | -$5.18 | $0 | |||
| 03/30/2020 | Q1 2020 | -$5.18 | $0 |
Entrada Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Entrada Therapeutics, Inc.'s earnings date?
Entrada Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based off last year's report dates.
-
Did Entrada Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Entrada Therapeutics, Inc. (:TRDA) reported $-0.35 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.67 by $0.32.
-
How can I listen to Entrada Therapeutics, Inc.'s earnings conference call?
The conference call for Entrada Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Entrada Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Entrada Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Entrada Therapeutics, Inc. generate each year?
Entrada Therapeutics, Inc. (:TRDA) has a recorded annual revenue of $129.01 M.
-
How much profit does Entrada Therapeutics, Inc. generate each year?
Entrada Therapeutics, Inc. (:TRDA) has a recorded net income of $129.01 M. Entrada Therapeutics, Inc. has generated $-0.2 earnings per share over the last four quarters.
-
What is Entrada Therapeutics, Inc.'s price-to-earnings ratio?
Entrada Therapeutics, Inc. (:TRDA) has a price-to-earnings ratio of 13.73 and price/earnings-to-growth ratio is -0.3.
